id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2008-D-0610-0002,FDA,FDA-2008-D-0610,Guidance for Industry - Postmarketing Adverse Event Reporting for Medical Products and Dietary Supplements During an Influenza Pandemic - Draft Guidance,Other,GDL-Guidance (Supporting and Related Materials),2008-12-16T05:00:00Z,2008,12,,,2009-02-19T17:57:41Z,,0,0,09000064807ddc44
FDA-2008-D-0610-0001,FDA,FDA-2008-D-0610,Draft Guidance for Industry on Postmarketing Adverse Event Reporting for Medical Products and Dietary Supplements During an Influenza Pandemic; Availability,Notice,NAD-Notice of Availability of Data,2008-12-16T05:00:00Z,2008,12,2008-12-16T05:00:00Z,2009-02-18T04:59:59Z,2009-02-19T17:59:49Z,,0,0,09000064807ddbf2